Patiromer in the Treatment of Hyperkalemia in Patients With Hypertension and Diabetic Nephropathy (AMETHYST-DN)
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 324 participants.
Also called NCT01371747
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 324 participants
- Sponsor
- Registry
-
NCT01371747 -
2011-000165-12
-
- Other papers using this trial's data
- Long-term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes/angiotensin receptor blockers: results from AMETHYST-DN
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Croatia, Georgia, Hungary, Serbia, Slovenia
- Registry status
- Completed
Technical summary
Registry record NCT01371747. Randomized; no masking; primary purpose treatment. Start 2011-06 (registry gives no type); primary completion 2013-05 (actual). Results posted on 2015-12-17.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Patiromer in the Treatment of Hyperkalemia in Patients With Hypertension and Diabetic Nephropathy (AMETHYST-DN)
- Acronym
- AMETHYST-DN
- Condition
- Chronic Kidney Disease
- Condition
- Hypertension
- Condition
- Hyperkalemia
- Intervention (Drug)
- patiromer
- Intervention (Drug)
- patiromer
- Intervention (Drug)
- patiromer
- Intervention (Drug)
- patiromer
- Intervention (Drug)
- patiromer
- Intervention (Drug)
- patiromer
- Intervention (Drug)
- losartan
- Intervention (Drug)
- spironolactone
- Lead sponsor
- Relypsa, Inc.
Record details
- Record id
cardio:ct-nct01371747- Content hash
2612c3b6eaddbff9d891b15f2ae9cb0ab4b42db1f1ffe0ceed4319ad0e201f65